New hope for myeloma patients with kidney issues: denosumab shows promise

NCT ID NCT02833610

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested the drug denosumab in 55 people with multiple myeloma and severe kidney problems. The goal was to see if it could help control bone damage caused by the cancer. Researchers measured changes in bone turnover markers and monitored side effects like low calcium and bone events over 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Mass General/North Shore Cancer Center

    Danvers, Massachusetts, 01923, United States

  • Massachusetts general Hospital

    Boston, Massachusetts, 02114, United States

  • Newton Wellesley Hospital

    Newton, Massachusetts, 02462, United States

  • University Hospitals of Cleveland

    Cleveland, Ohio, 44106, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States